logo
Plus   Neg
Share
Email

Ark Therapeutics Ink Manufacturing Pact With Laurantis Pharma - Quick Facts

Ark Therapeutics Group Plc (AKT.L) Monday announced that it has been selected to manufacture and supply Lymfactin to Laurantis Pharma under a conditional agreement.

The leading viral product focused contract development and manufacturing services company further stated that it has signed a manufacturing agreement with Laurantis Pharma, a privately held clinical-stage biotechnology company with a broad portfolio of first-in-class products based on two proprietary technologies, for Production of Lymfactin Investigational Treatment for Breast Cancer-Associated Lymphedema.

The Group stated that the agreement is subject to Laurantis receiving regulatory approval to commence its phase I clinical trial. Further, specific terms of the agreement between the two companies have not been disclosed.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Retail major Target Corp. is recalling about 44,350 units of Cat & Jack Baby Heart Ears Rompers, citing choking risks to children, the U.S. Consumer Product Safety Commission said in a statement. The recall involves rompers sold in various sizes from newborn to 24 months. The rompers were manufactured in Vietnam, and sold at Target stores across the United States and online. Alcoa Corp. (AA), the largest producer of aluminum in the US, Thursday reported a first-quarter profit that more than doubled from a year ago, driven by increased shipments and prices. Both adjusted earnings and revenues for the quarter trumped Wall Street analysts' estimates. Pittsburgh-based Alcoa... Walmart expects two-thirds of their Walmart U.S. hourly store roles to become full-time by the end of the current fiscal year, with consistent schedules from week to week, as part of their focus on creating even more opportunity for associates at Walmart.
Follow RTT